Comparison of robotic and laparoscopic surgery for sigmoid colon and rectal cancer: a single-center retrospective study on surgical outcomes and long-term survival
Journal of Robotic Surgery · 2024
DOI: 10.1007/s11701-024-02058-7 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Robotic Surgery, 2024. Verfasst von Jianhong Peng und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Colorectal Surgery, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-…. Hauptthemen laut MEDLINE: Robotic Surgical Procedures, Laparoscopy, Rectal Neoplasms, Sigmoid Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Science and Technology Projects in Guangzhou.
Abstract (Originalsprache)
Although the safety and short-term outcomes of robotic surgery for sigmoid colon and rectal cancer patients are well-documented, there is limited research on the long-term survival outcomes of robotic colorectal surgery. This is a retrospective study that includes 502 patients who underwent either laparoscopic or robotic anterior resection and abdominoperineal resection for rectal or sigmoid colon cancer between August 2016 and September 2021. All patients were diagnosed with rectal or sigmoid colon adenocarcinoma. Propensity score matching (PSM) was implemented to minimize selection bias. Perioperative outcomes, complication rates, and pathological data were evaluated and compared. The 5-year overall survival rate and disease-free survival rate were calculated and compared. Before matching, patients in the robotic group had earlier pathological T and N stages and were more likely to have received neoadjuvant chemoradiotherapy compared to the laparoscopic group. After matching, most clinicopathological outcomes were similar between the two groups, but the robotic group had longer operative times and a lower conversion rate to open surgery compared with laparoscopic group. After matching for clinical factors, the 5-year DFS rates were 88.19% for the robotic group and 82.46% for the laparoscopic group (P = 0.122), and the OS rates were 90.5% and 79.5% (P = 0.342), showing no significant differences. In the stratified analysis, patients in the robotic surgery group had significantly higher 5-year DFS rates in the following subgroups: age < 65 years, TNM stage I-II, received neoadjuvant therapy, and primary tumor located in the rectum. The safety and efficacy of robotic surgery for sigmoid colon and rectal cancer were validated compared to laparoscopic surgery, with both groups of patients exhibiting comparable long-term prognoses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Colorectal Surgery, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, 51006…
Förderung
- Science and Technology Projects in Guangzhou
Zitieren
APA
Peng, J., Zhang, W., Li, W., Ding, P., Lu, Z., Wu, X., Lin, J., & Pan, Z. (2024). Comparison of robotic and laparoscopic surgery for sigmoid colon and rectal cancer: a single-center retrospective study on surgical outcomes and long-term survival. Journal of Robotic Surgery. https://doi.org/10.1007/s11701-024-02058-7
Vancouver
Peng J, Zhang W, Li W, Ding P, Lu Z, Wu X, et al. Comparison of robotic and laparoscopic surgery for sigmoid colon and rectal cancer: a single-center retrospective study on surgical outcomes and long-term survival. Journal of Robotic Surgery. 2024. doi:10.1007/s11701-024-02058-7
BibTeX
@article{Peng2024,
author = {Peng, Jianhong and Zhang, Weili and Li, Weihao and Ding, Peirong and Lu, Zhenhai and Wu, Xiaojun and Lin, Junzhong and Pan, Zhizhong},
title = {Comparison of robotic and laparoscopic surgery for sigmoid colon and rectal cancer: a single-center retrospective study on surgical outcomes and long-term survival},
journal = {Journal of Robotic Surgery},
year = {2024},
doi = {10.1007/s11701-024-02058-7}
}
EUVIMED